Virtual support for obesity and kidney transplant access
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a patient-centered program with virtual support to help people with obesity and advanced kidney disease lose weight and improve their chances of getting a kidney transplant. It uses a type of medication called a GLP-1 receptor agonist, which can help with weight loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your body mass index (BMI) is greater than 35, which is considered severe obesity.
- Your kidney function is very low (eGFR less than 15) or you have a 10% or higher risk of needing dialysis or a transplant within 2 years.
- You do not have a history of pancreatitis, medullary thyroid cancer, or a family history of this cancer.
- You are not pregnant or breastfeeding.
- You do not have type 1 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a weight loss medication (semaglutide) can help manage obesity in people who have had a kidney transplant or are at high risk. It aims to improve health outcomes and prevent further kidney decline.
This Phase 2 study tests a program to help people with chronic kidney disease (CKD) sit less and move more, plus a medication (semaglutide) for those who qualify. It may help improve health and day-to-day activity while monitoring safety closely.
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can improve fat tissue health in people with chronic kidney disease who also have type 2 diabetes, cardiovascular disease, or obesity. It may help protect your kidneys and overall health.
This study tests a GLP-1 receptor agonist (a type of medicine that helps with weight and metabolism) in people with polycystic kidney disease who are overweight. It aims to see if this drug can help slow kidney disease progression.
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.